

Herve Avet-Loiseau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3856066/publications.pdf>

Version: 2024-02-01

394
papers

39,685
citations

3668

92
h-index

3417

189
g-index

406
all docs

406
docs citations

406
times ranked

21061
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.	0.6	64
2	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
3	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	2.5	19
4	Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma. <i>Leukemia</i> , 2022, 36, 881-884.	3.3	1
5	Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth. <i>Blood Advances</i> , 2022, 6, 672-678.	2.5	8
6	Molecular Signature of ¹⁸ F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1008-1013.	2.8	4
7	Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. <i>Blood</i> , 2022, 139, 2666-2672.	0.6	12
8	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. <i>Blood</i> , 2022, 139, 1160-1176.	0.6	11
9	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3150.	0.8	13
10	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. <i>Blood</i> , 2022, 139, 2747-2757.	0.6	16
11	MRD in multiple myeloma: does CR really matter?. <i>Blood</i> , 2022, 140, 2423-2428.	0.6	12
12	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <i>Leukemia</i> , 2021, 35, 573-584.	3.3	67
13	Common gene variants within 3' untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894.	2.3	3
14	Risk factors in multiple myeloma: is it time for a revision?. <i>Blood</i> , 2021, 137, 16-19.	0.6	37
15	del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , 2021, 137, 1192-1195.	0.6	48
16	Multiple Myeloma: Heterogeneous in Every Way. <i>Cancers</i> , 2021, 13, 1285.	1.7	15
17	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	2.8	10
18	No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , 2021, 194, 635-638.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2021, 39, 1139-1149.	0.8	57
20	Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods. <i>Leukemia</i> , 2021, 35, 3600-3603.	3.3	11
21	Requirements for operational cure in multiple myeloma. <i>Blood</i> , 2021, 138, 1406-1411.	0.6	10
22	The DNA methylation landscape of multiple myeloma shows extensive inter- and inpatient heterogeneity that fuels transcriptomic variability. <i>Genome Medicine</i> , 2021, 13, 127.	3.6	9
23	Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. <i>Blood</i> , 2021, 138, 2686-2695.	0.6	11
24	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1378-1390.	5.1	84
25	IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. <i>Blood</i> , 2021, 138, 1980-1985.	0.6	11
26	The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. <i>Leukemia</i> , 2020, 34, 167-179.	3.3	11
27	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e30-e37.	0.2	75
28	Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. <i>Immunity</i> , 2020, 53, 824-839.e10.	6.6	85
29	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3107-3118.	0.8	45
30	Risk and Response-Adapted Treatment in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3497.	1.7	10
31	Cerebrospinal Fluid Penetration of Daratumumab in Leptomeningeal Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e413.	1.2	8
32	Revealing the Impact of Structural Variants in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 258-273.	2.6	81
33	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	6.9	32
34	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5988-5999.	2.5	198
35	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111.	2.8	13
36	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146

#	ARTICLE	IF	CITATIONS
37	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. <i>Clinical Epigenetics</i> , 2020, 12, 163.	1.8	9
38	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. <i>Haematologica</i> , 2020, 105, e480-483.	1.7	42
39	Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3854.	1.8	7
40	MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide+dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	1.1	8
41	CNV Radar: an improved method for somatic copy number alteration characterization in oncology. <i>BMC Bioinformatics</i> , 2020, 21, 98.	1.2	8
42	Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells. <i>Stem Cells International</i> , 2020, 2020, 1-9.	1.2	5
43	Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. <i>Leukemia</i> , 2020, 34, 1866-1874.	3.3	36
44	Clinical benefit of ixazomib plus lenalidomide+dexamethasone in myeloma patients with non-canonical NF- κ B pathway activation. <i>European Journal of Haematology</i> , 2020, 105, 274-285.	1.1	7
45	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1917.	5.8	99
46	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
47	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , 2020, 136, 39-39.	0.6	70
48	The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia. <i>Blood</i> , 2020, 136, 48-49.	0.6	4
49	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.	3.3	313
50	Monoclonal Gammopathy May Be of Unpredictable Significance. <i>JAMA Oncology</i> , 2019, 5, 1302.	3.4	3
51	A practical guide for mutational signature analysis in hematological malignancies. <i>Nature Communications</i> , 2019, 10, 2969.	5.8	145
52	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. <i>Nature Communications</i> , 2019, 10, 3835.	5.8	183
53	High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. <i>Blood</i> , 2019, 133, 1217-1221.	0.6	79
54	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 29-38.	6.3	665

#	ARTICLE	IF	CITATIONS
55	Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4224-4230.	3.2	12
56	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1657-1665.	0.8	111
57	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 39.	2.8	38
58	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330.	3.3	33
59	Cytogénétique et génétique moléculaire du myélome multiple. <i>Revue Francophone Des Laboratoires</i> , 2019, 2019, 50-57.	0.0	1
60	Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e228-e237.	0.2	11
61	Risk-Based Therapeutic Strategies. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 54-58.	1.0	4
62	Multiple myeloma immunophenotyping: method validation. <i>Hematologie</i> , 2019, 25, 248-272.	0.0	0
63	Introduction to a review series on advances in multiple myeloma. <i>Blood</i> , 2019, 133, 621-621.	0.6	11
64	Carfilzomib weekly 20/56 mg/m ² , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E17-E20.	2.0	5
65	Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma (IFM 2012-03).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8029-8029.	0.8	1
66	Weekly 20/56 mg/m ² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8041-8041.	0.8	0
67	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. <i>Cancer Cell</i> , 2018, 33, 634-648.e5.	7.7	163
68	Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. <i>Annals of Hematology</i> , 2018, 97, 831-837.	0.8	0
69	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
70	Prognosis of Myeloma/Genetics of Myeloma. , 2018, , 645-649.		0
71	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , 2018, 32, 2626-2635.	3.3	48
72	Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. <i>Leukemia</i> , 2018, 32, 1267-1276.	3.3	18

#	ARTICLE	IF	CITATIONS
73	Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Bone Marrow Transplantation, 2018, 53, 749-755.	1.3	18
74	Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia, 2018, 32, 111-119.	3.3	42
75	Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia, 2018, 32, 376-382.	3.3	16
76	Heavy+light chain analysis to assign myeloma response is analogous to the IMWG response criteria. Leukemia and Lymphoma, 2018, 59, 583-589.	0.6	3
77	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2018, 24, 641-648.	2.0	19
78	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia, 2018, 32, 1043-1047.	3.3	87
79	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	0.6	216
80	Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 675-680.	1.8	23
81	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood, 2018, 132, 2778-2780.	0.6	18
82	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Reports, 2018, 25, 3693-3705.e6.	2.9	23
83	Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Advances, 2018, 2, 2811-2813.	2.5	69
84	Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica, 2018, 103, 2088-2096.	1.7	187
85	Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica, 2018, 103, 2079-2087.	1.7	225
86	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132, 2456-2464.	0.6	301
87	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2018, 32, 2604-2616.	3.3	137
88	TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood, 2018, 132, 1689-1694.	0.6	198
89	Genomic patterns of progression in smoldering multiple myeloma. Nature Communications, 2018, 9, 3363.	5.8	163
90	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood, 2018, 132, 587-597.	0.6	335

#	ARTICLE	IF	CITATIONS
91	Multiple myeloma clonal evolution in homogeneously treated patients. <i>Leukemia</i> , 2018, 32, 2636-2647.	3.3	94
92	Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 190-190.	0.6	1
93	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor. <i>Blood</i> , 2018, 132, 3272-3272.	0.6	17
94	Biologie du myélome multiple : utilité clinique. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 923-934.	0.0	0
95	Critical Role for Apobec and Its Interacting Partners in Mediating Mutations and Cell Growth in Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 4462-4462.	0.6	0
96	Light Chain Escape in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1881-1881.	0.6	2
97	The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis. <i>Blood</i> , 2018, 132, 109-109.	0.6	0
98	The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 3273-3273.	0.6	1
99	Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control. <i>Blood</i> , 2018, 132, 4500-4500.	0.6	2
100	Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation – Results from the Tourmaline-MM1 Study. <i>Blood</i> , 2018, 132, 473-473.	0.6	0
101	Genomics of Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 963-967.	0.8	85
102	Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , 2017, 129, 2429-2436.	0.6	214
103	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017, 23, 3980-3993.	3.2	71
104	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.	0.6	619
105	Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. <i>Cancer</i> , 2017, 123, 3701-3708.	2.0	12
106	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	13.9	924
107	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	0.6	90
108	Logic programming reveals alteration of key transcription factors in multiple myeloma. <i>Scientific Reports</i> , 2017, 7, 9257.	1.6	20

#	ARTICLE	IF	CITATIONS
109	Expressed fusion gene landscape and its impact in multiple myeloma. Nature Communications, 2017, 8, 1893.	5.8	31
110	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2017, , .	3.3	9
111	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	2.3	8
112	Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma. JAMA Oncology, 2017, 3, 28.	3.4	405
113	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. Leukemia, 2017, , .	3.3	11
114	Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. Frontiers in Physiology, 2017, 8, 149.	1.3	17
115	Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy. Journal of Clinical Oncology, 2017, 35, 2863-2865.	0.8	27
116	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Journal of Clinical Oncology, 2017, 35, 2911-2918.	0.8	247
117	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (Dvd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. Journal of Clinical Oncology, 2017, 35, 8006-8006.	0.8	18
118	Abstract 5719: Long intergenic non-coding RNAs: a new independent risk predictors in multiple myeloma. , 2017, , .		0
119	Abstract 5490: Non-overlapping promoter and super-enhancer-associated dependencies in multiple myeloma. , 2017, , .		0
120	Optimizing therapy for del(17p) multiple myeloma. Oncotarget, 2017, 8, 109859-109860.	0.8	0
121	Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e425-e430.	1.8	14
122	Light chain multiple myeloma: when the response will it be evaluated by serum free light chains?. Hematologie, 2016, 22, 393-394.	0.0	0
123	IgM ^κ and IgM ^λ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia. Clinical Cancer Research, 2016, 22, 5152-5158.	3.2	9
124	Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood, 2016, 128, 2941-2948.	0.6	58
125	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research, 2016, 22, 4350-4355.	3.2	38
126	Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica, 2016, 101, 356-362.	1.7	25

#	ARTICLE	IF	CITATIONS
127	Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du My��lome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2125-2132.	0.8	91
128	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	0.6	179
129	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
130	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood</i> , 2016, 127, 2569-2574.	0.6	224
131	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
132	A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e467-e467.	2.8	59
133	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
134	BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. <i>Journal of Experimental Medicine</i> , 2016, 213, 1705-1722.	4.2	24
135	Gene Expression Profiles in Myeloma: Ready for the Real World?. <i>Clinical Cancer Research</i> , 2016, 22, 5434-5442.	3.2	53
136	Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. <i>Annals of Oncology</i> , 2016, 27, 902-907.	0.6	10
137	Gene signature combinations improve prognostic stratification of multiple myeloma patients. <i>Leukemia</i> , 2016, 30, 1071-1078.	3.3	55
138	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
139	Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du My��lome (IFM) Krd Phase II Study. <i>Blood</i> , 2016, 128, 1142-1142.	0.6	36
140	Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma. <i>Blood</i> , 2016, 128, 116-116.	0.6	4
141	Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern. <i>Blood</i> , 2016, 128, 2088-2088.	0.6	1
142	Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial. <i>Blood</i> , 2016, 128, 2138-2138.	0.6	6
143	A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 238-238.	0.6	2
144	Final Analysis of Overall Survival from the First Trial. <i>Blood</i> , 2016, 128, 241-241.	0.6	11

#	ARTICLE	IF	CITATIONS
145	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 243-243.	0.6	3
146	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , 2016, 128, 246-246.	0.6	28
147	A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications. <i>Blood</i> , 2016, 128, 356-356.	0.6	1
148	Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du My��lome (IFM). <i>Blood</i> , 2016, 128, 674-674.	0.6	16
149	Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e425-e430.	1.8	13
150	Abstract 5023: Multiple myeloma with a clonal del17p aberration is characterized by somatic TP53 mutations, which negatively affect prognosis in this cytogenetic subgroup. , 2016, , .		0
151	The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing. <i>Blood</i> , 2016, 128, 236-236.	0.6	0
152	The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma. <i>Blood</i> , 2016, 128, 196-196.	0.6	2
153	RNA-Seq De Novo Assembly of Clonal Immunoglobulin Rearrangements Identifies Interesting Biology and Uncovers Prognostic Features in Multiple Myeloma. <i>Blood</i> , 2016, 128, 195-195.	0.6	10
154	Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis. <i>Blood</i> , 2016, 128, 3271-3271.	0.6	2
155	Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. <i>Blood</i> , 2015, 126, 2713-2719.	0.6	92
156	Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. <i>Blood</i> , 2015, 126, 1996-2004.	0.6	106
157	Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. <i>Blood</i> , 2015, 125, 1411-1417.	0.6	91
158	Radiolabelling rituximab with ^{99m} Tc in three steps procedure. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 274-280.	0.5	5
159	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
160	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4607-4618.	3.2	271
161	Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Soci��t�� Fran��aise de Greffe de Moelle et de Th��rapie Cellulaire (SFGM-TC). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1452-1459.	2.0	8
162	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 3100-3104.	0.6	47

#	ARTICLE	IF	CITATIONS
163	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. <i>Blood</i> , 2015, 125, 2095-2100.	0.6	82
164	Genetics of multiple myeloma: another heterogeneity level?. <i>Blood</i> , 2015, 125, 1870-1876.	0.6	107
165	Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. <i>Haematologica</i> , 2015, 100, e56-e59.	1.7	34
166	XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells. <i>Blood</i> , 2015, 126, 1218-1218.	0.6	1
167	Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 191-191.	0.6	50
168	Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma. <i>Blood</i> , 2015, 126, 21-21.	0.6	8
169	Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance. <i>Blood</i> , 2015, 126, 2420-2420.	0.6	2
170	Differentially Expressed and Prognostically Significant Lincrnas May Impact Immune System and Tumor Progression in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 2989-2989.	0.6	3
171	Genomic Landscape and Its Prognostic Implications in Multiple Myeloma Using a Targeted Sequencing Approach. <i>Blood</i> , 2015, 126, 370-370.	0.6	1
172	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015, 126, 391-391.	0.6	99
173	Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial. <i>Blood</i> , 2015, 126, 393-393.	0.6	10
174	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 395-395.	0.6	20
175	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. <i>Blood</i> , 2015, 126, 730-730.	0.6	15
176	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	0.6	8
177	The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact. <i>Blood</i> , 2015, 126, 835-835.	0.6	1
178	Redefining Mutational Profiling Using RNA-Seq: Insight into the Functional Mutational Landscape of Multiple Myeloma. <i>Blood</i> , 2015, 126, 837-837.	0.6	2
179	Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. <i>PLoS ONE</i> , 2015, 10, e0136505.	1.1	6
180	Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8578-8578.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Abstract 3035: HDAC8 is recruited to DNA double strand breaks sites and affects the homologous recombination efficiency in multiple myeloma. , 2015, , .		0
182	Functional and Genomic Signatures of Homologous Recombination (HR) Predict for Clinical Outcome in Multiple Myeloma (MM). Blood, 2015, 126, 3626-3626.	0.6	0
183	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. Blood, 2015, 126, 3049-3049.	0.6	0
184	Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma. Blood, 2015, 126, 4187-4187.	0.6	0
185	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. Blood, 2015, 126, 1770-1770.	0.6	4
186	Critical Role of Split Hand/Foot Malformation Type 1 (SHFM1) in Homologous Recombination and Cell Survival in Multiple Myeloma (MM). Blood, 2015, 126, 3625-3625.	0.6	0
187	Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 4212-4212.	0.6	0
188	Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia, 2014, 28, 1129-1131.	3.3	45
189	IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer, 2014, 120, 3952-3957.	2.0	29
190	IMWG consensus on risk stratification in multiple myeloma. Leukemia, 2014, 28, 269-277.	3.3	500
191	Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia, 2014, 28, 675-679.	3.3	91
192	A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets. Clinical Cancer Research, 2014, 20, 1135-1145.	3.2	85
193	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications, 2014, 5, 2997.	5.8	741
194	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia, 2014, 28, 525-542.	3.3	214
195	Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia, 2014, 28, 2229-2234.	3.3	67
196	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. New England Journal of Medicine, 2014, 371, 906-917.	13.9	697
197	Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du My��lome. Journal of Clinical Oncology, 2014, 32, 2712-2717.	0.8	243
198	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression��Related Death. Journal of Clinical Oncology, 2014, 32, 2173-2180.	0.8	150

#	ARTICLE	IF	CITATIONS
199	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. <i>Haematologica</i> , 2014, 99, 1236-1238.	1.7	35
200	NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. <i>Blood</i> , 2014, 123, 2816-2825.	0.6	36
201	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014, 124, 3110-3117.	0.6	54
202	Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial. <i>Blood</i> , 2014, 124, 180-180.	0.6	3
203	Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment. <i>Blood</i> , 2014, 124, 2005-2005.	0.6	1
204	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. <i>Blood</i> , 2014, 124, 2036-2036.	0.6	1
205	A Next Generation Sequencing-Based Approach to Detect Gene Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. <i>Blood</i> , 2014, 124, 3364-3364.	0.6	2
206	Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability. <i>Blood</i> , 2014, 124, 3417-3417.	0.6	2
207	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014, 124, 638-638.	0.6	25
208	in Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparay IFM Study. <i>Blood</i> , 2014, 124, 641-641.	0.6	3
209	Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma. <i>Blood</i> , 2014, 124, 721-721.	0.6	1
210	A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus. <i>Blood</i> , 2014, 124, 2057-2057.	0.6	0
211	Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma. <i>Blood</i> , 2014, 124, 3466-3466.	0.6	1
212	Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 2055-2055.	0.6	0
213	Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2. <i>Blood</i> , 2014, 124, 4714-4714.	0.6	0
214	Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System. <i>Blood</i> , 2014, 124, 3358-3358.	0.6	0
215	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2056-2056.	0.6	0
216	Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma. <i>Blood</i> , 2014, 124, 642-642.	0.6	0

#	ARTICLE	IF	CITATIONS
217	8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma. <i>Medical Oncology</i> , 2013, 30, 489.	1.2	9
218	Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. <i>Experimental Hematology</i> , 2013, 41, 1008-1015.	0.2	19
219	Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. <i>Cancer</i> , 2013, 119, 3680-3686.	2.0	30
220	Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. <i>Leukemia and Lymphoma</i> , 2013, 54, 767-777.	0.6	49
221	Prognostic Implication of Genetic Changes (Cytogenetics, and FISH, Gains and Losses of DNA by SNP) Tj ETQq1 1 0.784314 rgBT /Over		
222	Minor clone provides a reservoir for relapse in multiple myeloma. <i>Leukemia</i> , 2013, 27, 473-481.	3.3	112
223	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. <i>Leukemia</i> , 2013, 27, 711-717.	3.3	174
224	The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2013, 19, 4634-4637.	3.2	12
225	Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience. <i>Journal of Clinical Oncology</i> , 2013, 31, 2806-2809.	0.8	103
226	Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. <i>Blood</i> , 2013, 121, 1968-1975.	0.6	201
227	Prognostic utility of intact immunoglobulin IgA/IgG ratios in multiple myeloma patients. <i>Leukemia</i> , 2013, 27, 202-207.	3.3	69
228	Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial. <i>Blood Cancer Journal</i> , 2013, 3, e154-e154.	2.8	7
229	The shaping and functional consequences of the dosage effect landscape in multiple myeloma. <i>BMC Genomics</i> , 2013, 14, 672.	1.2	16
230	Myeloma: a subclonal disease?. <i>Hematologie</i> , 2013, 19, 383-387.	0.0	0
231	Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e59127.	1.1	29
232	Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor. <i>Blood</i> , 2013, 122, 124-124.	0.6	10
233	Bendamustine, Bortezomib and Dexamethasone (BVD) In Elderly Patients With Multiple Myeloma In First Relapse: Final Analysis Of The Intergroupe Francophone Du Myélome (IFM) 2009-01 Trial. <i>Blood</i> , 2013, 122, 1971-1971.	0.6	1
234	Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3106-3106.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance. <i>Blood</i> , 2013, 122, 3139-3139.	0.6	2
236	Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 401-401.	0.6	6
237	Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial. <i>Blood</i> , 2013, 122, 406-406.	0.6	41
238	Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14). <i>Blood</i> , 2013, 122, 689-689.	0.6	9
239	First Large Prospective Study For Patients With Primary Plasma Cell Leukemia: Bortezomib-Doxorubicine-Dexamethasone/Bortezomib-Cyclophosphamide-Dexamethasone Regimens As Induction Before Stem Cell Transplantation Followed By Consolidation With Lenalidomide-Bortezomib-Dex Or Allograft. (a study of the IFM group). <i>Blood</i> , 2013, 122, 761-761.	0.6	2
240	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.	0.6	56
241	Classify Hyperdiploidy Status of Multiple Myeloma Patients Using Gene Expression Profiles. <i>PLoS ONE</i> , 2013, 8, e58809.	1.1	11
242	Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd. <i>Blood</i> , 2013, 122, 3221-3221.	0.6	0
243	Functional and Molecular Impact Of Dp1-Dependent Alternate Splicing In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1845-1845.	0.6	0
244	Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial. <i>Blood</i> , 2013, 122, 3312-3312.	0.6	0
245	Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution. <i>Blood</i> , 2013, 122, 399-399.	0.6	0
246	Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. <i>Leukemia</i> , 2012, 26, 158-159.	3.3	44
247	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.	1.9	48
248	Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. <i>Journal of Clinical Oncology</i> , 2012, 30, 1949-1952.	0.8	198
249	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1782-1791.	13.9	1,022
250	Molecular Cytogenetic Aberrations in Tunisian Patients with Multiple Myeloma Identified by clg-FISH in Fixed Bone Marrow Cells. <i>Cytogenetic and Genome Research</i> , 2012, 136, 44-49.	0.6	3
251	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. <i>Haematologica</i> , 2012, 97, 784-791.	1.7	49
252	Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. <i>Haematologica</i> , 2012, 97, 1272-1277.	1.7	254

#	ARTICLE	IF	CITATIONS
253	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
254	Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and "retreatment" approaches in the era of novel agents. <i>Leukemia</i> , 2012, 26, 73-85.	3.3	74
255	Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012, 26, 595-608.	3.3	217
256	Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. <i>Cancer Research</i> , 2012, 72, 1395-1406.	0.4	90
257	Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study. <i>Blood</i> , 2012, 120, 196-196.	0.6	2
258	Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience. <i>Blood</i> , 2012, 120, 204-204.	0.6	3
259	Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells. <i>Blood</i> , 2012, 120, 4043-4043.	0.6	5
260	Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial. <i>Blood</i> , 2012, 120, 4044-4044.	0.6	4
261	The Combination of ISS 3, High LDH and t(4;14) and/or Del(17p) Identify a Simple Prognostic Index for Overall Survival in Patients Treated with Novel Agents-Based Induction Therapy and Front-Line Autologous Stem Cell Transplantation, and Allow the Definition of a Subgroup of Patients At High-Risk of Early Death From Progressive Disease. <i>Blood</i> , 2012, 120, 598-598.	0.6	1
262	1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients. <i>Blood</i> , 2012, 120, 933-933.	0.6	13
263	Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myelome (IFM) 2009-01 protocol.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8014-8014.	0.8	4
264	Are Stromal Cells of Adipose Tissue From Multiple Myeloma Patients Are Normal ? A Comparison of Adipose Derived Stromals Cells From Healthy Donors and Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 3993-3993.	0.6	0
265	DNA Copy Number Changes Have Gene Dosage Effects with Consequent Impact On Disease Biology and Prognosis in Multiple Myeloma. <i>Blood</i> , 2012, 120, 3984-3984.	0.6	0
266	Characterization of TFDP1 As Novel Regulatory Gene in Multiple Myeloma. <i>Blood</i> , 2012, 120, 569-569.	0.6	4
267	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	0.6	377
268	Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 1898-1906.	0.8	126
269	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2011, 37, 266-283.	3.4	66
270	Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>Haematologica</i> , 2011, 96, 1504-1511.	1.7	48

#	ARTICLE	IF	CITATIONS
271	Ultra high-risk myeloma: definition, identification, management. <i>Hematologie</i> , 2011, 17, 145-149.	0.0	0
272	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. <i>Blood</i> , 2011, 117, 2009-2011.	0.6	115
273	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. <i>Blood</i> , 2011, 117, 3041-3044.	0.6	109
274	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	0.6	849
275	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	0.6	285
276	ABT-737 is highly effective against molecular subgroups of multiple myeloma. <i>Blood</i> , 2011, 118, 3901-3910.	0.6	106
277	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. <i>Blood</i> , 2011, 118, 675-678.	0.6	160
278	Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , 2011, 118, 5752-5758.	0.6	275
279	The Impact of Genomics on the Management of Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1200-1206.	2.3	9
280	The dChip survival analysis module for microarray data. <i>BMC Bioinformatics</i> , 2011, 12, 72.	1.2	9
281	Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. <i>Haematologica</i> , 2011, 96, 1728-1732.	1.7	48
282	Genomics in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1234-1242.	3.2	84
283	Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications. <i>Journal of Clinical Oncology</i> , 2011, 29, 1893-1897.	0.8	74
284	Reply to W. Tapper et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e40-e41.	0.8	5
285	Significant Biological Role of Sp1 Transactivation in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 6500-6509.	3.2	47
286	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , 2010, 95, 1973-1976.	1.7	124
287	MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. <i>Blood</i> , 2010, , .	0.6	13
288	Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du My�lome (IFM). <i>Blood</i> , 2010, 115, 32-37.	0.6	152

#	ARTICLE	IF	CITATIONS
289	Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>Leukemia</i> , 2010, 24, 623-628.	3.3	130
290	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. <i>Leukemia</i> , 2010, 24, 1121-1127.	3.3	677
291	Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. <i>Leukemia</i> , 2010, 24, 1233-1235.	3.3	34
292	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). <i>Journal of Clinical Oncology</i> , 2010, 28, 4630-4634.	0.8	383
293	Reply to K. Filanovsky et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e117-e118.	0.8	0
294	Ultra High-Risk Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 489-493.	0.9	64
295	Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4621-4629.	0.8	512
296	Abstract 1978: The poly-SUMO protein specific E3 ubiquitin ligase RNF4 is induced in multiple myeloma and reduces bortezomib-induced cell killing. , 2010, , .		0
297	Loss of the SMRT/NCOR2 Corepressor Correlates with JAG2 Overexpression in Multiple Myeloma. <i>Cancer Research</i> , 2009, 69, 4380-4387.	0.4	64
298	Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4585-4590.	0.8	258
299	Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. <i>Leukemia</i> , 2009, 23, 806-807.	3.3	26
300	International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. <i>Leukemia</i> , 2009, 23, 2210-2221.	3.3	775
301	Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 5720-5726.	0.8	155
302	Genetic Changes in Myeloma: Prognostic Implications. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S8-S9.	1.4	1
303	The role of complete response in multiple myeloma. <i>Blood</i> , 2009, 114, 3139-3146.	0.6	206
304	Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 1800-1800.	0.6	1
305	The Functional Role of Microrna 15a/16-1 as Tumor Suppressor Genes in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1963-1963.	0.6	0
306	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. <i>Blood</i> , 2009, 114, 2846-2846.	0.6	3

#	ARTICLE	IF	CITATIONS
307	CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. <i>Leukemia Research</i> , 2008, 32, 379-382.	0.4	56
308	Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia. <i>Leukemia</i> , 2008, 22, 1056-1059.	3.3	22
309	Persistence of CD33 expression at relapse in CD33 ⁺ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. <i>British Journal of Haematology</i> , 2008, 143, 744-746.	1.2	20
310	Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 5192-5197.	0.8	79
311	Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome. <i>Journal of Clinical Oncology</i> , 2008, 26, 4798-4805.	0.8	361
312	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008, 112, 1329-1337.	0.6	439
313	Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. <i>Blood</i> , 2008, 112, 3914-3915.	0.6	110
314	Alternate Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A High-Density Exon Array Analysis of Uniformly Treated Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 498-498.	0.6	2
315	Expression Profile Signature to Predict Response to Bortezomib and Dexamethasone Combination Therapy in Newly-Diagnosed Myeloma: Moving towards Prospective Prediction. <i>Blood</i> , 2008, 112, 2746-2746.	0.6	0
316	Stem Cell Transplantation in Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 311-316.	0.9	10
317	The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. <i>Haematologica</i> , 2007, 92, 1335-1342.	1.7	199
318	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. <i>Blood</i> , 2007, 109, 3489-3495.	0.6	845
319	Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. <i>Lancet, The</i> , 2007, 370, 1209-1218.	6.3	820
320	Reactive plasmacytoses can mimic plasma cell leukemia: Therapeutical implications. <i>Leukemia and Lymphoma</i> , 2007, 48, 207-208.	0.6	19
321	Role of genetics in prognostication in myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 625-635.	0.7	68
322	Rituximab in CD20 positive multiple myeloma. <i>Leukemia</i> , 2007, 21, 835-836.	3.3	53
323	Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. <i>Leukemia</i> , 2007, 21, 2020-2024.	3.3	84
324	Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. <i>Human Pathology</i> , 2006, 37, 415-421.	1.1	41

#	ARTICLE	IF	CITATIONS
325	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006, 108, 3289-3294.	0.6	639
326	Lack of CD27 in myeloma delineates different presentation and outcome. <i>British Journal of Haematology</i> , 2006, 132, 168-170.	1.2	49
327	High Grade Non-Hodgkin's Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.. <i>Blood</i> , 2006, 108, 2045-2045.	0.6	4
328	Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2005, 29, 1003-1007.	0.4	37
329	Genetic heterogeneity in multiple myeloma. <i>Leukemia</i> , 2005, 19, 191-194.	3.3	35
330	Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. <i>Leukemia</i> , 2005, 19, 275-278.	3.3	109
331	Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. <i>Leukemia</i> , 2005, 19, 1248-1252.	3.3	292
332	CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. <i>Leukemia</i> , 2005, 19, 2021-2022.	3.3	37
333	Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Cancer Research</i> , 2005, 11, 7297-7303.	3.2	55
334	International Staging System for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3412-3420.	0.8	2,404
335	Stem-cell transplantation in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 603-618.	0.7	21
336	CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. <i>Haematologica</i> , 2005, 90, 706-7.	1.7	49
337	Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. <i>Haematologica</i> , 2005, 90, 1516-23.	1.7	28
338	Genetics and Cytogenetics of Multiple Myeloma. <i>Cancer Research</i> , 2004, 64, 1546-1558.	0.4	642
339	Formalin-Fixed and Paraffin-Embedded Nodal Non-Hodgkin's Lymphomas Demonstrate the Same Chromosome Changes as Those Found in Frozen Samples: A Comparative Study Using Interphase Fluorescence In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 2004, 13, 97-104.	2.1	8
340	Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. <i>Blood</i> , 2004, 103, 2727-2737.	0.6	127
341	Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. <i>Blood</i> , 2004, 103, 3869-3875.	0.6	35
342	Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. <i>Blood</i> , 2004, 104, 3697-3704.	0.6	164

#	ARTICLE	IF	CITATIONS
343	Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma.. Blood, 2004, 104, 4857-4857.	0.6	1
344	Overexpression of Her-2/neu Is Observed in One Third of Adult B-ALL Patients and Is Associated with Chemoresistance in These Patients.. Blood, 2004, 104, 524-524.	0.6	2
345	Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica, 2004, 89, 547-51.	1.7	53
346	Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. Haematologica, 2004, 89, 1399-401.	1.7	15
347	14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 153-155.	0.8	68
348	Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients. Leukemia, 2003, 17, 255-259.	3.3	54
349	Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup. Leukemia, 2003, 17, 1679-1682.	3.3	71
350	t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia, 2003, 17, 2032-2035.	3.3	101
351	CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 2003, 102, 1070-1071.	0.6	170
352	Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood, 2003, 101, 4998-5006.	0.6	124
353	Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood, 2003, 101, 1570-1571.	0.6	164
354	A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood, 2003, 101, 4975-4981.	0.6	275
355	CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood, 2002, 99, 4154-4159.	0.6	197
356	Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 2002, 99, 2185-2191.	0.6	332
357	Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood, 2002, 100, 1579-1583.	0.6	301
358	Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. Blood, 2002, 100, 1101-1104.	0.6	10
359	Current treatment strategies for multiple myeloma. European Journal of Internal Medicine, 2002, 13, 85-95.	1.0	7
360	Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genetics and Cytogenetics, 2002, 136, 121-125.	1.0	57

#	ARTICLE	IF	CITATIONS
361	CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 116, 142-150.	1.2	108
362	Large deletions 5q2 to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 1752-1754.	3.3	20
363	Expression pattern, genomic structure and evaluation of the human SLC30A4 gene as a candidate for acrodermatitis enteropathica. <i>Human Genetics</i> , 2001, 109, 178-185.	1.8	23
364	Ca ²⁺ -sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids. <i>Journal of Gene Medicine</i> , 2001, 3, 153-164.	1.4	145
365	High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. <i>Human Mutation</i> , 2001, 18, 212-224.	1.1	168
366	Characterization of Adenovirus-Induced Inverted Terminal Repeat-Independent Amplification of Integrated Adeno-Associated Virus rep-cap Sequences. <i>Journal of Virology</i> , 2001, 75, 375-383.	1.5	31
367	Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: Relation to morphology, cell proliferation and expression of breast cancer-related genes. <i>International Journal of Cancer</i> , 2000, 89, 403-410.	2.3	18
368	Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 350-352.	1.5	6
369	IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. <i>British Journal of Haematology</i> , 2000, 109, 71-80.	1.2	16
370	Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. <i>British Journal of Haematology</i> , 2000, 111, 1116-1117.	1.2	10
371	Reply to Drach et al. <i>British Journal of Haematology</i> , 2000, 108, 887-887.	1.2	1
372	Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF. <i>Leukemia Research</i> , 2000, 24, 627-630.	0.4	9
373	Fluorescence In Situ Hybridization on Peripheral-Blood Specimens Is a Reliable Method to Evaluate Cytogenetic Response in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 1533-1538.	0.8	52
374	14q32 chromosomal translocations: a hallmark of plasma cell dyscrasias?. <i>The Hematology Journal</i> , 2000, 1, 292-294.	2.0	6
375	Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. <i>British Journal of Haematology</i> , 2000, 111, 1116-1117.	1.2	83
376	Reply to Drach et al. <i>British Journal of Haematology</i> , 2000, 108, 887-887.	1.2	0
377	P53 deletion is not a frequent event in multiple myeloma. <i>British Journal of Haematology</i> , 1999, 106, 717-719.	1.2	62
378	Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. <i>British Journal of Cancer</i> , 1999, 79, 1843-1847.	2.9	59

#	ARTICLE	IF	CITATIONS
379	High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. , 1999, 24, 9-15.		84
380	Amplification of the 11q23 region in acute myeloid leukemia. , 1999, 26, 166-170.		51
381	Genetic alterations in early-onset invasive breast carcinomas: Correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype. , 1999, 84, 511-515.		9
382	Detection of Translocation t(11;14)(q13;q32) in Mantle Cell Lymphoma by Fluorescence in Situ Hybridization. American Journal of Pathology, 1999, 154, 1449-1452.	1.9	189
383	FISH Analysis at Diagnosis in Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1999, 33, 441-449.	0.6	19
384	Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. , 1998, 23, 175-182.		51
385	Recent Human-Specific Spreading of a Subtelomeric Domain. Genomics, 1998, 51, 165-176.	1.3	45
386	Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. , 1998, 23, 175.		1
387	N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Soci�t� Francaise d'Oncologie P�diatrique.. Journal of Clinical Oncology, 1997, 15, 1171-1182.	0.8	169
388	Construction of a 780-kb PAC, BAC, and Cosmid Contig Encompassing the Minimal Critical Deletion Involved in B Cell Chronic Lymphocytic Leukemia at 13q14.3. Genomics, 1997, 46, 183-190.	1.3	43
389	Comparative genomic hybridization is a powerful tool, complementary to cytogenetics, to identify chromosomal abnormalities in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 1997, 99, 589-596.	1.2	22
390	Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas. British Journal of Haematology, 1997, 97, 119-122.	1.2	44
391	Rothmund-Thomson syndrome and osteosarcoma. , 1996, 26, 414-416.		21
392	Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. , 1996, 17, 156-165.		90
393	Clonal Hematologic Disorders in Down Syndrome A Review. Journal of Pediatric Hematology/Oncology, 1995, 17, 19-24.	0.3	40
394	Morphologic and molecular cytogenetics in neuroblastoma. Cancer, 1995, 75, 1694-1699.	2.0	26